
    
      Patients with ESRD will be treated with a dose escalation of ribavirin starting from 200 mg
      everyday (QD) to a maximal tolerated dose. Peginterferon will then be added. Ribavirin will
      be dose adjusted as needed. Boceprevir will then be added. Ribavirin will be dose adjusted as
      needed. Patients will be monitored for eRVR and SVR. The study end-point is eRVR.
    
  